Recruiting A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL NCT06484920 Conditions B-cell Lymphoma, Hemic and Lymphatic Diseases, Hodgkin Disease, +13 more Locations Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana, United States Sidney and Lois Eskenazi Hospital — Indianapolis, Indiana, United States View Trial Details
Completed Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma NCT04052997 Conditions Disease Attributes, Hemic and Lymphatic Diseases, Hodgkin Disease, +12 more Locations Mayo Clinic - Arizona — Scottsdale, Arizona, United States City of Hope Comprehensive Cancer Center — Duarte, California, United States UCSF Health - Hematology and Blood and Marrow Transplant Clinic — San Francisco, California, United States Stanford University Medical Center — Stanford, California, United States View all 73 locations View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma NCT04134325 Conditions Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +8 more Locations Lineberger Comprehensive Cancer Center at University of North Carolina — Chapel Hill, North Carolina, United States View Trial Details
